This page will lead you to information about OTT’s services and processes related to invention disclosures, patent prosecution, technology marketing, confidential disclosure agreements, and the distribution of license revenue.
Also be sure to take a look at three of OTT’s success stories. Each started with the submission of an invention disclosure to OTT by faculty and physicians engaged in basic and/or clinical research at TJU. Through OTT’s aggressive marketing and sound licensing structure, the commercial partners have diligently developed the technologies into therapeutic products currently in clinical testing. In return, the license revenue distributed by OTT recognizes and rewards the problem-solving ingenuity of the inventors and returns the investment made by TJU to support future innovations.
OTT is guided in its operating procedure by pertinent TJU polices, in particular, the Patent Policy, Equity Policy, and Tangible Research Property Policy. In addition, OTT often consults with the TJU senior management, including the VP for Research and the VP for Finance.
OTT also encourages and seeks further partnership opportunities with the potential licensee, through sponsored research in the lead inventor candidate’s laboratory and/or consulting arrangements for the inventor candidate(s).
Finally, OTT leverages its industry contacts by connecting faculty members with potential commercial partners to explore collaboration opportunities and related funding support.
In the News
Science Center's QED Proof-of-Concept program
Finalists are awarded up to $200,000 and receive guidance from business advisors
Opening date for White Papers: April 14, 2014
Deadline for early submission to receive feedback: May 16, 2014
Final deadline for White Papers: June 13, 2014
Jan. 24, 2014 at 8:30-10am
JAH Au Bon Pain (Mezzanine)